<DOC>
	<DOCNO>NCT01615354</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , cross-over study assess effect aleglitazar pharmacokinetics pharmacodynamics MicrogynonÂ® healthy volunteer . Volunteers receive multiple oral dos aleglitazar one period ; period volunteer receive placebo .</brief_summary>
	<brief_title>A Study Aleglitazar Combination With Oral Contraceptive Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Healthy female volunteer , 18 45 year age Body mass index ( BMI ) 18.0 29.9 kg/m2 Body weight least 55.0 kg Nonpregnant , lactate plan pregnancy screen 3 month last dose study treatment Nonsmoker least 3 month Currently active gynecological disorder History amenorrhea within previous 3 year Known suspected history estrogendependent neoplasia sex hormonedependent malignant tumor Use steroid hormonecontaining intrauterine device ( IUD ) progesteronerelease IUD contraceptive within 3 month screen . History clinically significant disease could jeopardize volunteer safety study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>